Pharmacokinetics, Safety and Tolerability of BI 201335 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase I Trial
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2015
At a glance
- Drugs Faldaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Oct 2013 Results will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) according to a Boehringer Ingelheim media release.
- 27 Jun 2012 Actual patient number (28) added as reported by ClinicalTrials.gov.
- 27 Jun 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.